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216a Monday, March 7, 2011a bacterial DNA replication enzyme beginning with a fragment based lead gen-
eration approach will be presented. In this approach, biochemical, biophysical
and structural tools were employed to screen fragment libraries against the tar-
get enzyme and progress initial hits to drug-like leads. The availability of high-
resolution target structure provided valuable chemistry guidance in designing
such leads.
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ROSETTAEPR: An Integrated Tool for Protein Structure Determination
From Sparse EPR Data
Stephanie Hirst, Nathan Alexander, Hassane S. Mchaourab, Jens Meiler.
Membrane proteins remain a particular challenge in structural biology. Only
about 1.5% of reported tertiary structures and 60 unique membrane protein to-
pologies consisting of more than one transmembrane span are represented in
the PDB. However, these proteins make up an estimated 30-40% of the entire
proteome, and over half of all therapeutics target this group. Site-directed spin
labeling electron paramagnetic resonance (SDSL-EPR) is often used for the
structural characterization of proteins that elude other techniques, such as X-
ray crystallography and NMR. However, high-resolution structures are difficult
to obtain due to uncertainty in the spin label location and sparseness of exper-
imental data. ROSETTAEPR has been designed to improve high-resolution
protein structure prediction using sparse SDSL-EPR distance data. The ‘‘mo-
tion-on-a-cone’’ spin label model is converted into a knowledge-based poten-
tial, which was implemented as a scoring term in ROSETTA. We have
demonstrated the feasibility of using ROSETTAEPR with soluble proteins
by benchmarking the method on T4-lysozyme. ROSETTAEPR increased the
fractions of correctly folded models (RMSDC < 7.5A˚) and models accurate
at medium resolution (RMSDC < 3.5A˚) by 25%. After full-atom refinement,
ROSETTAEPR yielded a 1.7A˚ model of T4-lysozyme, thus indicating that
atomic detail models can be achieved by combining sparse EPR data with RO-
SETTA. ROSETTAEPR was also benchmarked on a set of membrane proteins
of known structure. If EPR experimental data were not available, simulated
data were derived from the existing structures. It was generally observed that
de novo folding in the presence of EPR restraints enriched the recovery of
the proteins’ correct topology compared to when folding with no restraints.
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Incorporating the Effects of pH in Protein-Protein Docking
Krishna Praneeth Kilambi, Jeffrey J. Gray.
Highly charged interfaces often frustrate protein-protein docking methods.
Current approaches do not account for changes in the ionization states which
may play a crucial role in binding. Predicting the charges on the residues would
be the first step towards understanding the dependence of docking on pH. We
developed a method to predict the pKa values of the common ionizable residues
in proteins (Asp, Glu, Lys, His and Tyr) . It incorporates conformational flex-
ibility through extensive amino-acid side-chain rotamer sampling and is based
on the Rosetta energy function with an explicit term to account for the proton-
ation state probabilities of the amino-acids. In approximately 80% of the cases,
the method predicts the pKa value of a residue to an accuracy of 1 pH unit from
the experimental value and 95% of the time it predicts a value within 2 units of
pH. The method is comparable in accuracy to the other published computa-
tional pKa prediction methods and is fast enough to be used to dynamically
predict and alter the ionization states of the amino-acid side chains during pro-
tein-protein docking. We expect the new protocol to lead to improvements in
conformational sampling during docking as well as help in the discrimination
and ranking of the generated ensemble of tentative protein complexes.
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Mechanism and Action of Flufirvitide, a Peptide Inhibitor of Influenza
Virus Infection
Hussain Badani, Robert F. Garry, Russell B. Wilson, William C. Wimley.
Influenza is an infectious disease typically transmitted through the air. It is re-
sponsible for seasonal epidemics affecting millions of people, and sporadic
global pandemics. Influenza infection is a membrane fusion-dependant process,
occurring in the endosome of the host cell after viral binding and endocytosis.
The virus-host membrane fusion process is mediated by hemagglutinin (HA),
a viral surface glycoprotein. Studies show that when the virus is subjected to
low pH in the endosome, the HA protein partially unfolds and changes confor-
mation, exposing the fusion initiation region (FIR). A 16 amino acid peptide
sequence (Flufirvitide) derived from the fusion initiation region of the HA pro-
tein has shown effective inhibition of influenza virus infection. It is hypothe-
sized that there is an interaction between the peptide and the FIR which
inhibits fusion of the virus to the host cell. Plaque inhibition assays and animal
studies show high efficacy of the peptide against the virus. We are currently de-
veloping biochemical and biophysical assays to study the interaction between
Flufirvitide and HA. Circular Dichroism studies show that the peptide has a ran-dom coil conformation at pH 7 and higher. To elucidate the mechanism of fu-
sion inhibition, the interaction between peptide and HA is being investigated
with immunodetection, immunoprecipitation, and florescence techniques. Ad-
ditionally, binding and interaction of the peptide with the intact virus is being
studied by using Cryo-electron microscopy.
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Computational Design of Small Molecules with Druglike Properties
D.S. Dalafave, K.S. Jani.
Many cancers overexpress antiapoptotic proteins,which can lead to poor chemo-
therapy response. This work reports on computational design of druglike small
molecules that could potentially facilitate apoptosis by forming complexes with
antiapoptotic proteins. Drugs based on small molecules that target a single pro-
tein can lead to drug resistance. On the other hand, a drug that operates too
broadly may harm healthy tissue. An alternative is a drug that can bind two or
more of the proteins. A single drug would be more economical and lead to fewer
side effects than a combination of drugs with each one targeting a single protein.
In this work, structures of experimentally known small molecules were used as
templates to design new molecules. Common structural features of the experi-
mental molecules were identified. The Osiris Property Explorer program was
employed to study how the features influenced molecular druglike properties.
Atomic substitutions and structuralmodificationswere done to design new small
molecules.Drug-related properties andpotential toxicities of themoleculeswere
determined and compared to those of commercial drugs. Molecules with no in-
dicated toxic risks and optimal values of drug-related properties were used for
docking studies in the ArgusLab program. Binding energies of stable configura-
tions of the designed molecules and antiapoptotic proteins were calculated. De-
signed molecules that made the most stable complexes with two or more
antiapoptotic proteins were identified. The potential to use the designed mole-
cules in anticancer drug design is discussed.
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Total Synthesis of Moscatilines and Wedelolactones as Potential Inhibitors
of Anti-Metastic Agents in MDA-MB-231 Cells
Yean-Jang Lee, Wen-Shing Tsau, Chia-Fu Cheng, Tsui-Hwa Tseng,
Pei-Yun Huang, Shien-Kai Chuang.
Combretastatins, which are an important group of anticancer drugs, were iso-
lated by Pettit et al. from the African tree Combretum caffrum in 1989. Addi-
tionally, Liang et al. have reported that ten coumestans were isolated from the
roots of Hedysarum multijugum, which is a plant in Hedysarum Linn. of the
family Leguminosae used as a folk herbal drug in northwest China. Coumestans
comprise a class of naturally occurring products with a variety of biological ac-
tivities including phytoestrogenic, antibacterial, antifungal, antimyotoxic, and
phytoalexine effects. Due to their biological activities, the synthesis of Hedy-
sarimcoumestan B is achieved in which the longest linear sequence is only
eight steps in 50% overall yield from commercially available phloroglucinol.
The key transformations in the synthesis are Stille coupling and DDQ oxida-
tive-cyclization reactions. This synthetic strategy can be applied to give access
to the demethylwedelolactone and wedelolactone, which were afforded from a-
bromocoumarin in high 55% and 47% yields, respectively. In addition, CA-4
analogues are also synthesized by Pd-catalyzed coupling in overall yield
20~28%. Furthmore, the molecular model was examined the interactions of
proteins and ligands as well. Finally, the bioassay results show that the anti-in-
vasion and anti-metastsis activity of wedelolactones in breast cancer are asso-
ciated with inhibition of signaling pathway and promotion of chromatin
remodeling. Camphorataimide B reduced the size and weigth of lung as well
as lung colonization of MDA-MB-231 cells.
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In Silico Approach to Identify Substrates and Inhibitors of Malaria Prote-
ases
Lauren E. Boucher, Jenny Lundqvist, Holly L. Hammond, Ju¨rgen Bosch.
Malaria affects over 500 million people and causes 1.3 million deaths annually.
The parasite, Plasmodium falciparum, is responsible for the most deadly vari-
ant of malaria in humans. Due to evolving resistance to current treatments, it is
necessary to develop new drugs targeting the parasite. Potential drug targets are
the malaria proteases; several proteases are critical in both the liver and blood
stages of the parasite’s life cycle, essential for both invasion and egress of cells.
Proteases have been effective drug targets for the treatment of several diseases
evidenced by the development of HIV protease inhibitors, ACE inhibitors treat-
ing hypertension, and anticoagulants treating thrombosis.
In developing new therapies, we are taking a structure-based drug design ap-
proach to design inhibitors of proteases key to parasite survival. While several
vital proteases have been identified, relatively little else is known and substrates
for many proteases have yet to be identified. To identify these substrates, we are
using an in silico approach to screen for peptides that bind to the protease active
